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A nationally funded diagnostic service should lead to improved
outcome
T
he National Specialist Commissioning
Advisory Group (NSCAG) has funded
three centres to establish and provide a
national diagnostic service for England for
children and adults suspected of suffering
from primary ciliary dyskinesia (PCD). This
is welcomed, as state of the art diagnostic
testing will be available nationally which
will increase the numbers of patients
diagnosed with a condition in which early
diagnosis has a very significant effect on
both short-term and long-term morbidity.
Inheritance is autosomal recessive with an
incidence of around 1:15 000 in the
Caucasian population and, as expected,
we have found a much higher incidence
in ethnic groups where consanguineous
marriages are common. Accurate diagnosis
will allow appropriate genetic counselling
of families.
PCD is caused by one of a number of
different ciliary defects that result in
ineffective mucociliary clearance.
Although most patients with PCD have
symptoms from birth or early infancy,1
the diagnosis is frequently delayed2 and it
is likely that a significant number of
patients are never diagnosed.3 Failure to
diagnose PCD leads to progressive and
permanent lung destruction owing to
obstruction of the airways with secretions
and subsequent infection, leading to
bronchiectasis. Early diagnosis of PCD is
important as deterioration in lung func-
tion can largely be prevented by specialist
respiratory care.4 Failure to recognise the
condition frequently leads to inappropri-
ate ear, nose and throat (ENT) surgery.
Grommet insertion may lead to persistent
aural discharge with little improvement
in hearing loss. A number of patients
with unrecognised PCD present in infer-
tility clinics. Infertility in males, although
not inevitable, is due to sperm tails being
affected as part of their PCD. There is an
increased incidence of ectopic pregnancy
due to defective movement of the cilia in
the fallopian tube.5
As PCD testing is not a front line test
for those with respiratory problems, who
should be referred? Patients with situs
inversus, which occurs in 40–50% of
individuals with PCD, is an obvious
indication. Of patients referred to our
laboratory with situs inversus, 75% have
been confirmed to have PCD. Of patients
without situs inversus, those with
bronchiectasis and life-long nasal symp-
toms in whom no other cause has been
identified should be considered for refer-
ral. A significant number of patients with
PCD will have a history of unexplained
neonatal respiratory distress and persis-
tent rhinitis from birth. The real aim,
however, is to diagnose children before
bronchiectasis develops and before they
are subjected to repeated ENT surgery.
The investigation of children with host
defence problems—including PCD—who
are at risk of developing bronchiectasis is
frequently delayed. Reasons for the delay
include the child’s tendency to swallow
rather than expectorate sputum, a dis-
tinct lack of auscultatory findings and
temperature even during acute exacerba-
tions, and the fact that the chest radio-
graph often appears normal.
So, how do we recognise a young child
at risk of developing bronchiectasis? The
important sign is that of a persistent
‘‘wet’’ sounding cough. If such a cough
persists for more than 8 weeks or
improvement is seen with antibiotic
treatment but symptoms return when
stopped, paediatric review should be
arranged. In patients with PCD the cough
never goes completely even with treat-
ment and ‘‘has always been there’’.
Testing for PCD should be considered if
standard first line investigations to
exclude cystic fibrosis (CF) and screening
for immunological defects are negative
and the child has a life-long history of a
‘‘wet’’ sounding cough and persistent
nasal symptoms. A number of patients
will have a history of unexplained neo-
natal respiratory distress. Hearing pro-
blems are only seen in half of cases. If the
child is from a consanguineous marriage,
suspicion should be higher. Nonetheless,
symptoms may be mild; in one series,
diagnosis was made in 10% as a result of
family screening after the diagnosis in an
index case.6
Diagnosis to date has largely been
provided on an ad hoc basis, with lack
of standardisation of, and inaccessibility
to, diagnostic testing for the majority of
patients in the UK. Screening tests for
PCD exist, but there are problems asso-
ciated with them. The saccharin test used
to assess mucociliary function is difficult
to perform and is unreliable in children.
Measurement of nasal nitric oxide, which
is very low in patients with PCD, is now
accepted as the most sensitive and spe-
cific screening test for PCD.7
Unfortunately this is not widely available
and cannot be used in young children.
The development of new methodologies
over the last few years has allowed
improved diagnostic testing for PCD. The
traditional measurement of ciliary beat
frequency alone has been shown to miss a
proportion of patients with PCD whose
ciliary beat frequency is normal but beat
pattern abnormal.8 Diagnostic assessment
following biopsy will now include mea-
surement of ciliary beat frequency, high
speed analysis of ciliary beat pattern,8
detailed electron microscopy of ciliary
ultrastructure and, in cases where there
are diagnostic uncertainties, cell culture9
from biopsies. Although the genetics of
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PCD are slowly being unravelled, owing
to the multiple phenotypes of the disease
and more than 200 different proteins
used to construct the ciliary axoneme, it
is likely to be some time before such tests
are widely used in the diagnostic exam-
ination of patients with PCD.
The diagnostic service is able to accept
appropriate referrals from hospital con-
sultants. However, the service does not
extend to providing care for patients
diagnosed with PCD. As experience of
care for patients with PCD is limited, we
would suggest a model similar to that for
CF where patients should have access to a
specialist paediatric respiratory consul-
tant or thoracic physician with an interest
in CF or non-CF bronchiectasis and be
followed up regularly for life. The diag-
nostic service will allow a national data-
base of patients with PCD to be
established, facilitating clinical trials to
help provide an evidence base for man-
agement. An active PCD patient and
parent support group has been estab-
lished which we encourage newly diag-
nosed patients to contact (www.
pcdsupport.org.uk).
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Biomarkers need to fulfil several distinct requirements before they can
be considered a valid indicator of chronic diseases such as COPD
C
hronic obstructive pulmonary dis-
ease (COPD) has become recognised
as a priority area for management of
healthcare resources and development of
new therapeutic strategies. This is based
largely on economic burden and the
excessive morbidity and mortality asso-
ciated with the condition. The result has
been a profusion of publications in recent
years, many of which start with the
observations that ‘‘COPD is currently the
fifth and by the year 2020 will become the
third or fourth leading cause of morbidity
and mortality worldwide’’.
More recently, the COPD literature has
entered a second phase. This has arisen
from the appreciation that COPD is more
than a respiratory inflammatory condition
and is associated with manifestations out-
side the lung. This has led to the concept
that COPD is a systemic disease and has
resulted in a rapid increase in papers
exploring this aspect. Initial studies were
primarily based on the association of
reduced body mass index with severe
COPD and common inflammatory path-
ways have been implicated.1 In particular,
the central role of tumour necrosis factor
(TNF)a has been proposed,2 and muscle
biopsies in patients with COPD have shown
apoptotic changes within skeletal muscle3
thought to be the result of the systemic
inflammation.
In addition to the association of skeletal
muscle dysfunction, it is also being appre-
ciated that other co-morbidities such as
cardiovascular disease,4 type II diabetes5
and osteoporosis6 are more commonly
associated with patients with COPD than
the general population. Indeed, the inflam-
matory basis for these other conditions is
also gradually becoming appreciated, and
there are many common pathogenic pro-
cesses between them and COPD.1
Research in COPD is now entering
its third phase. Many pharmaceutical
companies are becoming involved in drug
discovery programmes based on the
development of new treatments to mod-
ulate the inflammatory processes in COPD.
However, as with all chronic diseases, the
progression of COPD is slow but contin-
uous. Thus, not only does the complexity of
the inflammatory pathway present a chal-
lenge to research workers and pharmaceu-
tical companies, but also the conventional
pathway of progressing from drug discov-
ery through phase I and phase II to phase
III controlled clinical trials is impaired by
the lack of early ‘‘read outs’’ in phase II.
The traditional surrogate for progres-
sion in COPD is a physiological measure-
ment (forced expiratory volume in 1 s
(FEV1)) which can vary day-to-day more
than the overall progression over several
years. Thus, although many drugs have
been developed and marketed based on
FEV1 and evidence of symptomatic relief,
the progression of the disease has
remained unaltered. As interventions
related to progression require many years
of physiological follow-up, pharmaceuti-
cal companies have been hampered by
the lack of specific or surrogate markers
(closely linked to the pathogenic process
in COPD) that are sensitive to facilitate
short-term phase II proof of concept
studies. Since these are the key to
subsequent investment in large and
lengthy phase III studies, there is an
urgent need to identify such biomarkers.
Understanding the inflammatory process
involved in the pathophysiology of chronic
diseases such as COPD provides the poten-
tial to identify more robust surrogate
markers of the disease process that are
sensitive to short-term interventions.
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